

Hiroyoshi Takeuchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6627708/publications.pdf>

Version: 2024-02-01

143
papers

3,552
citations

136950

32
h-index

175258

52
g-index

157
all docs

157
docs citations

157
times ranked

4430
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination Therapy of Long-Acting Injectable Second-Generation Antipsychotics and Oral Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 81-86.	1.4	2
2	Association between subjective distress and symptom domains in patients with treatment-resistant schizophrenia receiving clozapine. <i>Schizophrenia Research</i> , 2022, 240, 228-230.	2.0	0
3	The promise and pitfalls of antipsychotic co-initiation in schizophrenia. <i>Lancet Psychiatry</i> , 2022, 9, 262-263.	7.4	1
4	Clozapine Once-Daily Versus Divided Dosing Regimen. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 163-168.	1.4	7
5	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	3.3	107
6	Priapism and Second-Generation Antipsychotics: Disproportionality Analysis of a Spontaneous Reporting System Database in Japan. <i>Psychiatry and Clinical Neurosciences</i> , 2022, 76, 525-526.	1.8	1
7	Risk of withdrawal of consent for treatment with long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled trials. <i>Schizophrenia Research</i> , 2021, 229, 94-101.	2.0	2
8	Comprehensive assessment of exposure to clozapine in association with side effects among patients with treatment-resistant schizophrenia: a population pharmacokinetic study. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532110161.	2.7	1
9	Evaluation of pharyngeal swallowing pressure using high-resolution manometry during transoral surgery for oropharyngeal cancer. <i>Journal of Laryngology and Otology</i> , 2021, 135, 153-158.	0.8	1
10	Antipsychotic Medications: Enhancing Use to Improve Outcomes. <i>Schizophrenia Bulletin</i> , 2021, 47, 1201-1204.	4.3	2
11	Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia. <i>Behavioural Brain Research</i> , 2021, 402, 113098.	2.2	36
12	Development of diagnostic criteria and severity scale for polydipsia: A systematic literature review and well-experienced clinicians' consensus. <i>Psychiatry Research</i> , 2021, 297, 113708.	3.3	1
13	Neuroleptic malignant syndrome associated with long-acting injectable versus oral second-generation antipsychotics: Analyses based on a spontaneous reporting system database in Japan. <i>Schizophrenia Research</i> , 2021, 231, 42-46.	2.0	8
14	Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms. <i>Human Psychopharmacology</i> , 2021, 36, e2804.	1.5	5
15	Olanzapine Reduction From High Dose to Standard Dose. <i>Journal of Clinical Psychopharmacology</i> , 2021, Publish Ahead of Print, 676-680.	1.4	0
16	Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms. <i>Schizophrenia Research</i> , 2021, 236, 142-155.	2.0	18
17	Antipsychotic nonadherence measured by electronic adherence monitoring in stabilized chronic schizophrenia: Clinical implications. <i>Schizophrenia Research</i> , 2021, 237, 202-207.	2.0	1
18	Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial—EPOC 2 (JFMC49-1601-C5). <i>ESMO Open</i> , 2021, 6, 100277.	4.5	6

#	ARTICLE	IF	CITATIONS
19	Clinical features of catatonic non-convulsive status epilepticus: A systematic review of cases. <i>Journal of Psychosomatic Research</i> , 2021, 151, 110660.	2.6	5
20	Longitudinal changes in antipsychotic dose in patients treated with long-acting injectable second-generation antipsychotics. <i>International Clinical Psychopharmacology</i> , 2021, 36, 84-88.	1.7	3
21	Relationship between polydipsia and antipsychotics: A systematic review of clinical studies and case reports. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 96, 109756.	4.8	14
22	Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 11-22.	3.2	34
23	Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm. <i>CNS Drugs</i> , 2020, 34, 117-126.	5.9	10
24	Clozapine-related gastrointestinal perforation: four case reports. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 541-542.	2.3	2
25	Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials. <i>Neuropsychopharmacology</i> , 2020, 45, 887-901.	5.4	41
26	Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms. <i>Schizophrenia Research</i> , 2020, 215, 8-16.	2.0	49
27	Prescription patterns of psychotropics in patients receiving synthetic glucocorticoids. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 242-248.	4.5	1
28	Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis. <i>Schizophrenia Bulletin</i> , 2020, 46, 1439-1458.	4.3	22
29	Immediate versus wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis. <i>Journal of Psychopharmacology</i> , 2020, 34, 914-919.	4.0	3
30	Reliability of the Glasgow Antipsychotic Side-effects Scale for Clozapine Japanese version (GASS-C-J). <i>PLoS ONE</i> , 2020, 15, e0234864.	2.5	2
31	Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis. <i>CNS Drugs</i> , 2020, 34, 579-598.	5.9	55
32	Adherence to clozapine vs. other antipsychotics in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 87-95.	4.5	26
33	Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D ₂ Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	14
34	Circadian patterns of hallucinatory experiences in patients with schizophrenia: Potentials for chrono-pharmacology. <i>Journal of Psychiatric Research</i> , 2019, 117, 1-6.	3.1	7
35	Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2019, 209, 50-57.	2.0	27
36	The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 89, 207-213.	4.8	5

#	ARTICLE	IF	CITATIONS
37	Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 1036-1042.	5.4	116
38	Size of recurrent laryngeal nerve as a new risk factor for postoperative vocal cord paralysis. <i>Ecological Management and Restoration</i> , 2018, 31, .	0.4	6
39	Achievement motivation in early schizophrenia: Relationship with symptoms, cognition and functional outcome. <i>Microbial Biotechnology</i> , 2018, 12, 1038-1044.	1.7	16
40	Rapid vs. slow antipsychotic initiation in schizophrenia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2018, 193, 29-36.	2.0	15
41	F225. LEVODOPA AUGMENTATION OF ANTIPSYCHOTICS FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2018, 44, S309-S309.	4.3	1
42	Efficacy of fluoroscopy-guided endoscopic cricopharyngeal myotomy. <i>Journal of Laryngology and Otology</i> , 2018, 132, 1128-1133.	0.8	2
43	Can Aripiprazole Worsen Psychosis in Schizophrenia?. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 17r11489.	2.2	14
44	Evaluation of pharyngoœsophageal involvement in pemphigus vulgaris and its correlation with disease activity. <i>British Journal of Dermatology</i> , 2017, 176, 224-226.	1.5	5
45	Insight into illness and its relationship to illness severity, cognition and estimated antipsychotic dopamine receptor occupancy in schizophrenia: An antipsychotic dose reduction study. <i>Psychiatry Research</i> , 2017, 251, 20-25.	3.3	10
46	Gradual vs. wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis. <i>Schizophrenia Research</i> , 2017, 189, 4-8.	2.0	11
47	Factors associated with drug attitude in patients with schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2017, 188, 185-186.	2.0	3
48	Representativeness of clinical PET study participants with schizophrenia: A systematic review. <i>Journal of Psychiatric Research</i> , 2017, 88, 72-79.	3.1	6
49	Neurocognitive Benefits of Second-Generation Antipsychotics Versus Placebo. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 274-276.	1.4	7
50	One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis. <i>British Journal of Psychiatry</i> , 2017, 211, 137-143.	2.8	33
51	Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2017, 43, 764-777.	4.3	159
52	Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw171.	4.3	21
53	Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimerâ€™s Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 747-762.	2.6	9
54	The Effects of Cortical Hypometabolism and Hippocampal Atrophy on Clinical Trajectories in Mild Cognitive Impairment with Suspected Non-Alzheimerâ€™s Pathology: A Brief Report. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 341-347.	2.6	4

#	ARTICLE	IF	CITATIONS
55	Switching to Clozapine Using Immediate Versus Gradual Antipsychotic Discontinuation. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 223-228.	2.2	7
56	What symptom domains are associated with patient distress in schizophrenia?. <i>Schizophrenia Research</i> , 2016, 176, 329-330.	2.0	4
57	Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1193-1203.	2.4	60
58	Consistency between clinician and patient ratings of clozapine-induced side effects. <i>Schizophrenia Research</i> , 2016, 174, 200-201.	2.0	2
59	Reliability of a patient-reported outcome measure in schizophrenia: Results from back-to-back self-ratings. <i>Psychiatry Research</i> , 2016, 244, 415-419.	3.3	14
60	Using poverty of speech as a case study to explore the overlap between negative symptoms and cognitive dysfunction. <i>Schizophrenia Research</i> , 2016, 176, 411-416.	2.0	20
61	Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms. <i>Focus (American Psychiatric Publishing)</i> , 2016, 14, 396-402.	0.8	3
62	Incidence of Antipsychotic-Associated Side Effects. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 593-596.	1.4	4
63	Life satisfaction and happiness among young adults with schizophrenia. <i>Psychiatry Research</i> , 2016, 242, 174-179.	3.3	41
64	A preliminary examination of the validity and reliability of a new brief rating scale for symptom domains of psychosis: Brief Evaluation of Psychosis Symptom Domains (BE-PSD). <i>Journal of Psychiatric Research</i> , 2016, 80, 87-92.	3.1	11
65	Treating Negative Symptoms in Schizophrenia: an Update. <i>Current Treatment Options in Psychiatry</i> , 2016, 3, 133-150.	1.9	123
66	Clozapine administration in clinical practice: once-daily versus divided dosing. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 234-240.	4.5	17
67	Motivational deficits in major depressive disorder: Cross-sectional and longitudinal relationships with functional impairment and subjective well-being. <i>Comprehensive Psychiatry</i> , 2016, 66, 31-38.	3.1	22
68	Neurocognitive impairment in the deficit subtype of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 397-407.	3.2	21
69	Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study. <i>Pharmacopsychiatry</i> , 2015, 48, 286-291.	3.3	4
70	Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 743-754.	2.6	33
71	Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review. <i>Canadian Journal of Psychiatry</i> , 2015, 60, 215-222.	1.9	63
72	Language Barriers and Access to Psychiatric Care: A Systematic Review. <i>Psychiatric Services</i> , 2015, 66, 798-805.	2.0	68

#	ARTICLE	IF	CITATIONS
73	Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms. <i>Canadian Journal of Psychiatry</i> , 2015, 60, 515-522.	1.9	35
74	Effect of Antipsychotic Dosing Regimen on Neurocognition in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 728-730.	1.4	0
75	Positive Symptoms Are Associated With Clinicians'™ Global Impression in Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 237-241.	1.4	4
76	The Effect of Clozapine on Hematological Indices. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 510-516.	1.4	40
77	Optimization of psychopharmacotherapy for schizophrenia in a male, locked, non-acute unit serving for persistently ill patients over one year. <i>Psychiatry Research</i> , 2015, 228, 26-30.	3.3	1
78	Measuring motivation in people with schizophrenia. <i>Schizophrenia Research</i> , 2015, 169, 423-426.	2.0	19
79	Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. <i>Schizophrenia Research</i> , 2015, 161, 351-356.	2.0	32
80	Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data. <i>Schizophrenia Research</i> , 2015, 161, 429-433.	2.0	22
81	Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. <i>European Neuropsychopharmacology</i> , 2015, 25, 295-302.	0.7	8
82	Antipsychotics and Amotivation. <i>Neuropsychopharmacology</i> , 2015, 40, 1539-1548.	5.4	45
83	A questionnaire survey of Japanese non-psychiatrists'™ attitudes on management of depression in a general hospital. <i>Asian Journal of Psychiatry</i> , 2015, 15, 73-74.	2.0	1
84	Relationships between global assessment of functioning and other rating scales in clinical trials for schizophrenia. <i>Psychiatry Research</i> , 2015, 227, 265-269.	3.3	40
85	Neuroimaging findings in treatment-resistant schizophrenia: A systematic review. <i>Schizophrenia Research</i> , 2015, 164, 164-175.	2.0	75
86	Clinical and Functional Outcomes in People With Schizophrenia With a High Sense of Well-Being. <i>Journal of Nervous and Mental Disease</i> , 2015, 203, 187-193.	1.0	10
87	Relationship Between Symptomatic Improvement and Overall Illness Severity in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 128-133.	1.4	5
88	Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D _{2/3} receptor occupancy following risperidone and olanzapine dose reduction. <i>Evidence-Based Mental Health</i> , 2015, 18, 117-117.	4.5	2
89	Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia. <i>Schizophrenia Research</i> , 2015, 166, 304-309.	2.0	26
90	Determinants of Patient-Rated and Clinician-Rated Illness Severity in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 924-930.	2.2	17

#	ARTICLE	IF	CITATIONS
91	What does schizophrenia teach us about antipsychotics?. Canadian Journal of Psychiatry, 2015, 60, S14-8.	1.9	5
92	A review on schizophrenia and relapse—a quest for user-friendly psychopharmacotherapy. Human Psychopharmacology, 2014, 29, 414-426.	1.5	29
93	Lack of Effect of Risperidone or Olanzapine Dose Reduction on Metabolic Parameters, Prolactin, and Corrected QT Interval in Stable Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2014, 34, 517-520.	1.4	6
94	The neurobiology of relapse in schizophrenia. Schizophrenia Research, 2014, 152, 381-390.	2.0	30
95	Incidence of Deep Vein Thrombosis in Restrained Psychiatric Patients. Psychosomatics, 2014, 55, 69-75.	2.5	35
96	Preliminary development and evaluation of the support system for care of mechanically ventilated patients. British Journal of Anaesthesia, 2014, 113, 491-500.	3.4	3
97	Relationship between clinical improvement and functional gains with clozapine in schizophrenia. European Neuropsychopharmacology, 2014, 24, 1622-1629.	0.7	6
98	Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: Findings from the NIMH CATIE study. European Neuropsychopharmacology, 2014, 24, 1078-1085.	0.7	21
99	Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia. Psychiatry Research, 2014, 218, 244-246.	3.3	2
100	Impact of Once- Versus Twice-Daily Perphenazine Dosing on Clinical Outcomes. Journal of Clinical Psychiatry, 2014, 75, 506-511.	2.2	16
101	Dose Reduction of Risperidone and Olanzapine and Estimated Dopamine D ₂ Receptor Occupancy in Stable Patients With Schizophrenia. Journal of Clinical Psychiatry, 2014, 75, 1209-1214.	2.2	14
102	A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology, 2013, 228, 175-185.	3.1	35
103	Clinical determinants of life satisfaction in chronic schizophrenia: Data from the CATIE study. Schizophrenia Research, 2013, 151, 203-208.	2.0	35
104	Estimated dopamine D ₂ receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: An analysis of the CATIE data. Schizophrenia Research, 2013, 150, 373-379.	2.0	8
105	The potential role of dopamine D ₃ receptor neurotransmission in cognition. European Neuropsychopharmacology, 2013, 23, 799-813.	0.7	153
106	Risk of neutropenia in a clozapine-treated elderly population. Schizophrenia Research, 2013, 148, 183-185.	2.0	12
107	Life Satisfaction Among Individuals With Schizophrenia in the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) Study. American Journal of Psychiatry, 2013, 170, 1061-1062.	7.2	11
108	Effects of Risperidone and Olanzapine Dose Reduction on Cognitive Function in Stable Patients With Schizophrenia: An Open-Label, Randomized, Controlled, Pilot Study. Schizophrenia Bulletin, 2013, 39, 993-998.	4.3	92

#	ARTICLE	IF	CITATIONS
109	Complete Genome Sequences of Two Helicobacter pylori Bacteriophages Isolated from Japanese Patients. <i>Journal of Virology</i> , 2012, 86, 11400-11401.	3.4	32
110	Antipsychotic treatment for schizophrenia in the maintenance phase: A systematic review of the guidelines and algorithms. <i>Schizophrenia Research</i> , 2012, 134, 219-225.	2.0	100
111	The evolution of antipsychotic switch and polypharmacy in natural practice – A longitudinal perspective. <i>Schizophrenia Research</i> , 2011, 130, 40-46.	2.0	57
112	Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: A randomized open-label trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1983-1989.	4.8	38
113	Dopamine D2 Receptor Occupancy and Clinical Effects. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 497-502.	1.4	117
114	Predicting Dopamine D2 Receptor Occupancy From Plasma Levels of Antipsychotic Drugs. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 318-325.	1.4	77
115	How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review. <i>Journal of Psychiatric Research</i> , 2011, 45, 1083-1088.	3.1	6
116	Patient's trust in their psychiatrist: a cross-sectional survey. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 603-608.	3.2	10
117	Low Dose vs Standard Dose of Antipsychotics for Relapse Prevention in Schizophrenia: Meta-analysis. <i>Schizophrenia Bulletin</i> , 2011, 37, 788-799.	4.3	94
118	Magnitude of Rater Differences in Assessment Scales for Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 607-611.	1.4	9
119	Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study. <i>Psychiatry and Clinical Neurosciences</i> , 2010, 64, 104-106.	1.8	22
120	Analysis of Antipsychotic Dose Reduction. <i>American Journal of Psychiatry</i> , 2010, 167, 994-994.	7.2	2
121	Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. <i>Human Psychopharmacology</i> , 2009, 24, 628-638.	1.5	51
122	Survey of benzodiazepine and antidepressant use in outpatients with mood disorders in Japan. <i>Psychiatry and Clinical Neurosciences</i> , 2009, 63, 244-246.	1.8	20
123	Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: A survey of 796 outpatients in Japan. <i>Journal of Anxiety Disorders</i> , 2009, 23, 477-481.	3.2	37
124	Impacts of Switching Antidepressants After Successful Electroconvulsive Therapy on the Maintenance of Clinical Remission in Patients With Treatment-Resistant Depression. <i>Journal of ECT</i> , 2009, 25, 178-181.	0.6	3
125	Predictors of Clinical Worsening After a Switch to Aripiprazole in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 394-395.	1.4	18
126	Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. <i>Human Psychopharmacology</i> , 2008, 23, 455-463.	1.5	43

#	ARTICLE	IF	CITATIONS
127	Novel rating scales for schizophrenia – Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz). <i>Schizophrenia Research</i> , 2008, 106, 328-336.	2.0	27
128	A Randomized, Open-Label Comparison of 2 Switching Strategies to Aripiprazole Treatment in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 540-543.	1.4	32
129	An Open-Label Trial of Discontinuing Benzodiazepines in Patients With Chronic Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 401-403.	1.4	6
130	How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone? – A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. <i>Psychopharmacology</i> , 2007, 195, 285-295.	3.1	49
131	Combined Treatment With Sulpiride and Paroxetine for Accelerated Response in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 545-551.	1.4	20
132	Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. <i>Psychopharmacology</i> , 2005, 181, 566-575.	3.1	20
133	Bone mineral density measurement in female inpatients with schizophrenia. <i>Schizophrenia Research</i> , 2005, 77, 113-115.	2.0	15
134	Changes in thymus- and activation-regulated chemokine (TARC) associated with allergen immunotherapy in patients with perennial allergic rhinitis. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2005, 15, 172-6.	1.3	10
135	Increased peritoneal dissemination after laparotomy versus pneumoperitoneum in a mouse cecal cancer model. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2004, 18, 1795-1799.	2.4	14
136	Prognostic Significance of Natural Killer Cell Activity in Patients With Gastric Carcinoma: A Multivariate Analysis. <i>American Journal of Gastroenterology</i> , 2001, 96, 574-578.	0.4	111
137	Further evidence that altered p16/CDKN2 gene expression is associated with lymph node metastasis in squamous cell carcinoma of the esophagus. <i>Oncology Reports</i> , 2001, 8, 627-32.	2.6	7
138	Changes in unilateral nasal airflow in patients with seasonal allergic rhinitis measured in and out of season. <i>Auris Nasus Larynx</i> , 2000, 27, 141-145.	1.2	9
139	Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. <i>Clinical Cancer Research</i> , 1997, 3, 2229-36.	7.0	47
140	Detection of <i>Proteus mirabilis</i> Urease Gene in Urinary Calculi by Polymerase Chain Reaction. <i>International Journal of Urology</i> , 1996, 3, 202-206.	1.0	6
141	Fetal urine production at different gestational ages: correlation to various compromised fetuses in utero. <i>Early Human Development</i> , 1994, 40, 1-11.	1.8	36
142	A Case of a Compound Heterozygote for Adenine Phosphoribosyltransferase Deficiency (Aprt*J/Aprt*Q0) Leading to 2,8-Dihydroxyadenine Urolithiasis: Review of the Reported Cases with 2,8-Dihydroxyadenine Stones in Japan. <i>Journal of Urology</i> , 1993, 149, 824-826.	0.4	11
143	Effects of dietary calcium, magnesium and phosphorus on the formation of struvite stones in the urinary tract of rats. <i>Urological Research</i> , 1991, 19, 305-308.	1.5	12